ELUCIDATION OF STRUCTURAL REQUIREMENTS ON PLASMINOGEN-ACTIVATOR INHIBITOR-1 FOR BINDING TO HEPARIN

被引:0
|
作者
EHRLICH, HJ [1 ]
GEBBINK, RK [1 ]
KEIJER, J [1 ]
PANNEKOEK, H [1 ]
机构
[1] NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB,DEPT MOLEC BIOL, PLESMANLAAN 125, 1066 CX AMSTERDAM, NETHERLANDS
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasminogen activator inhibitor 1 (PAI-1), a member of the serpin superfamily of proteins, has been demonstrated previously to interact functionally with the glycosaminoglycan heparin (Ehrlich, H. J., Keijer, J., Preissner, K. T., Klein Gebbink, R., and Pannekoek, H. (1991) Biochemistry 30, 1021-1028). Heparin specifically enhances the rate of association between PAI-1 and thrombin about 2 orders of magnitude, whereas no effect is detected with other serine proteases (e.g. factor Xa). For the heparin-dependent serpins antithrombin III and heparin cofactor II, basic amino acid residues in and around the helix D subdomain were proposed to be involved in the binding of glycosaminoglycans. Here we employed site-directed mutagenesis of full-length PAI-1 cDNA to identify the amino acid residues that mediate heparin binding. To that end, 15 single-point mutants of PAI-1, each having individual arginyl, lysyl, or histidyl residues replaced by a neutral (alanyl) residue ("ala-scan"), and one double mutant were constructed, expressed in Escherichia coli, and purified to apparent homogeneity. The purified biologically active proteins were subjected to the following analyses: (i) heparin-dependent inhibition of thrombin; (ii) heparin-dependent formation of sodium dodecyl sulfate-stable complexes with thrombin; and (iii) binding to and elution from heparin-Sepharose. Based on the data presented, we propose that the amino acid residues Lys65, Lys69, Arg76, Lys80 and Lys88 constitute major determinants for heparin binding of PAI-1. These residues are located in and around the helix D domain and are conserved in the other heparin-dependent thrombin inhibitors, antithrombin III and heparin cofactor II.
引用
收藏
页码:11606 / 11611
页数:6
相关论文
共 50 条
  • [31] PLASMINOGEN-ACTIVATOR INHIBITOR-1 EXPRESSION IN MEGAKARYOCYTES AND PLATELETS
    KONKLE, BA
    SCHICK, PK
    ARTERIOSCLEROSIS, 1990, 10 (05): : A909 - A909
  • [32] PLASMINOGEN-ACTIVATOR INHIBITOR-1 EXPRESSION IN MEGAKARYOCYTES AND PLATELETS
    KONKLE, BA
    SCHICK, PK
    CIRCULATION, 1990, 82 (04) : 600 - 600
  • [33] VASCULAR REGULATION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY
    EDELBERG, JM
    SANE, DC
    PIZZO, SV
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1994, 20 (04): : 319 - 323
  • [34] MUTATIONAL AND IMMUNOCHEMICAL ANALYSIS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1
    SHUBEITA, HE
    COTTEY, TL
    FRANKE, AE
    GERARD, RD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (30) : 18379 - 18385
  • [35] A MODEL OF THE REACTIVE FORM OF PLASMINOGEN-ACTIVATOR INHIBITOR-1
    AERTGEERTS, K
    DEBONDT, HL
    DERANTER, C
    DECLERCK, PJ
    JOURNAL OF STRUCTURAL BIOLOGY, 1994, 113 (03) : 239 - 245
  • [36] INDEPENDENT REGULATION OF PLASMINOGEN-ACTIVATOR INHIBITOR-2 AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN HUMAN SYNOVIAL FIBROBLASTS
    HAMILTON, JA
    CHEUNG, D
    FILONZI, EL
    PICCOLI, DS
    WOJTA, J
    GALLICHIO, M
    MCGRATH, K
    LAST, K
    ARTHRITIS AND RHEUMATISM, 1992, 35 (12): : 1526 - 1534
  • [37] THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 BINDING-SITE IN THE KRINGLE-2 DOMAIN OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    KANEKO, M
    MIMURO, J
    MATSUDA, M
    SAKATA, Y
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 178 (03) : 1160 - 1166
  • [38] Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators
    Tucker, HM
    Gerard, RD
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 237 (01): : 180 - 187
  • [40] REVERSIBLE INTERACTIONS BETWEEN PLASMINOGEN ACTIVATORS AND PLASMINOGEN-ACTIVATOR INHIBITOR-1
    MIMURO, J
    KANEKO, M
    MURAKAMI, T
    MATSUDA, M
    SAKATA, Y
    BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1160 (03) : 325 - 334